Financial Comparison: Olympus (OCPNY) and The Competition

Olympus (OTCMKTS:OCPNY) is one of 515 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Olympus to related businesses based on the strength of its dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Dividends

Olympus pays an annual dividend of $0.08 per share and has a dividend yield of 0.4%. Olympus pays out 9.8% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.3% and pay out 52.3% of their earnings in the form of a dividend.

Valuation and Earnings

This table compares Olympus and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Olympus	$7.74 billion	$1.03 billion	21.95
Olympus Competitors	$1.88 billion	$143.04 million	8.42

Olympus has higher revenue and earnings than its competitors. Olympus is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and target prices for Olympus and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olympus	0	0	1	0	3.00
Olympus Competitors	4176	10253	17859	789	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 26.68%. Given Olympus’ competitors higher probable upside, analysts clearly believe Olympus has less favorable growth aspects than its competitors.

Profitability

This table compares Olympus and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Olympus	13.80%	24.30%	9.30%
Olympus Competitors	-275.43%	-157.35%	-22.23%

Institutional & Insider Ownership

0.0% of Olympus shares are held by institutional investors. Comparatively, 40.1% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Olympus has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Olympus’ competitors have a beta of 2.56, indicating that their average stock price is 156% more volatile than the S&P 500.

Summary

Olympus beats its competitors on 9 of the 15 factors compared.

About Olympus

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.